Investor Presentation
Summary by AI BETAClose X
Verici Dx plc
(“Verici Dx” or the “Company”)
Investor Presentation
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, will provide a live online presentation via Investor Meet Company at 16:30 GMT on Tuesday 27 October 2026. Sara Barrington, Chief Executive Officer, will discuss the Company’s successful recent fundraise, which management anticipates will provide sufficient runway to achieve cash-flow breakeven by the end of 2027.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Verici Dx via: https://www.investormeetcompany.com/verici-dx-plc/register-investor
Investors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.
|
Verici Dx plc |
||
|
Sara Barrington, CEO |
Via Walbrook PR |
|
|
Julian Baines, Chairman |
|
|
|
|
|
|
|
Singer Capital Markets |
Tel: +44 (0)20 7496 3000 |
|
|
Russell Cook / Anastassiya Eley / Harry Littlewood |
|
|
|
|
|
|
|
Oberon Capital |
Tel: +44 (0)20 3179 0500 |
|
|
Mike Seabrook / Heena Karani |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
|
|
Alice Woodings / Rachel Broad |
Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 |
|
|
|
|
|
About Verici Dx plc www.vericidx.com
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.
Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.
The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com and follow us on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Power Probe PLC
- 1 hour ago Primary Health Properties
- 1 hour ago IG Group Holdings
- 2 days ago City of London Investment Group
- 2 days ago Kooth